INNOVIVA, INC. Stockholders' Equity Attributable to Noncontrolling Interest
INNOVIVA, INC. (INVA) had Stockholders' Equity Attributable to Noncontrolling Interest of $0 as of 2022-12-31, per its 10-K filed 2023-02-28.
Discontinued › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest
us-gaap:MinorityInterest · last filed 2023-02-28
- 2022-12-31: Stockholders' Equity Attributable to Noncontrolling Interest $0.00.
- 2022-09-30: Stockholders' Equity Attributable to Noncontrolling Interest $0.00.
- 2022-06-30: Stockholders' Equity Attributable to Noncontrolling Interest $177.13M.
- 2022-03-31: Stockholders' Equity Attributable to Noncontrolling Interest $165.57M.
| Period end | Stockholders' Equity Attributable to Noncontrolling Interest |
|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-02-28 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-09 |
| 2022-06-30 | $177.13M 10-Q · filed 2022-07-27 |
| 2022-03-31 | $165.57M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $111.19M 10-K · filed 2023-02-28 |
| 2021-09-30 | $88.99M 10-Q · filed 2021-10-27 |
| 2021-06-30 | $63.97M 10-Q · filed 2021-07-29 |
| 2021-03-31 | $62.22M 10-Q · filed 2021-04-28 |
| 2020-12-31 | $67.92M 10-K/A · filed 2022-03-17 |
| 2020-09-30 | $49.32M 10-Q · filed 2020-10-28 |
| 2020-06-30 | $35.91M 10-Q · filed 2020-07-29 |
| 2020-03-31 | $26.33M 10-Q · filed 2020-04-29 |
| 2019-12-31 | $28.62M 10-K · filed 2021-02-25 |
| 2019-09-30 | $16.71M 10-Q · filed 2019-10-30 |
| 2019-06-30 | $20.02M 10-Q · filed 2019-07-24 |
| 2019-03-31 | $11.70M 10-Q · filed 2019-05-01 |
| 2018-12-31 | $5.47M 10-K · filed 2020-02-19 |
| 2018-09-30 | $3.08M 10-Q · filed 2018-10-31 |
| 2018-06-30 | $1.99M 10-Q · filed 2018-07-26 |
| 2018-03-31 | $811.00K 10-Q · filed 2018-05-04 |
| 2017-12-31 | $152.00K 10-K · filed 2019-02-19 |
| 2016-12-31 | $0.00 10-K · filed 2018-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |